The phenotypic landscape of essential human genes - Secondary live cell screen
收藏NIAID Data Ecosystem2026-05-01 收录
官方服务：
资源简介：
Large-scale, live cell imaging-based pooled CRISPR/Cas9 knockout screens to understand essential gene function.
应用场景：
创建时间：
2023-06-13
相关数据集
Gene expression in HeLa cells expressing GFP-IRF3 (non-targeting control and clonal knockouts of DDX58, MAVS, ATP13A1, CAPN15, TADA2B, MED16, and MED24) following Sendai virus (SeV) infection or hpRNA transfection. Gene expression in HeLa cells expressing GFP-IRF3 (non-targeting control and clonal knockouts of DDX58, MAVS, ATP13A1, CAPN15, TADA2B, MED16, and MED24) following Sendai virus (SeV) infection or hpRNA transfection
IRF3 translocates from the cytoplasm to the nucleus upon recognition of a cytoplasmic RNA stimulus by RIG-I or MDA5. Using an optical pooled CRISPR knockout screen in HeLa-Cas9 cells, we identified AT
NIAID Data Ecosystem50
Fitness during the T. gondii lytic cycle. (Genome-Wide CRISPR Screen)
Genome-wide loss of function screen (CRISPR) that measures each gene's contribution to Toxoplasma gondii fitness during infection of human fibroblasts. Phenotype s
NIAID Data Ecosystem40
DepMap 21Q4 Public
This DepMap release contains data from CRISPR knockout screens from project Achilles, as well as genomic characterization data from the CCLE project. For more information, please see README.txt.
Figshare2021-11-03 更新20
CRISPR RNA-seq from HepG2 (ENCSR284SZO)
RNA-seq on HepG2 cells treated with a CRISPR gRNA against EXOSC5. (EXOSC5-BGHcLV07) For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages
NIAID Data Ecosystem40
Effect of genom-wide depletion on gene expression during treatment with the JAK2 inhibitor Ruxolitinib of JAK2 mutated HEL erythroleukemia cells [CRISPR]. Effect of genom-wide depletion on gene expression during treatment with the JAK2 inhibitor Ruxolitinib of JAK2 mutated HEL erythroleukemia cells [CRISPR]
In order to confirm the functional dependency on KDM4C under treatment conditions with the JAK-inhibitor ruxolitinib (RUX), we applied a genome-wide CRISPR-Cas9 screen in the human JAK2-mutated cell l
NIAID Data Ecosystem20
